BioInvent International Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

BioInvent International şirketinin toplam hissedar öz sermayesi SEK1.0B ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK1.1B ve SEK84.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 950.11m
Eşitlik	SEK 1.00b
Toplam yükümlülükler	SEK 84.38m
Toplam varlıklar	SEK 1.09b

Son finansal sağlık güncellemeleri

Is BioInvent International (STO:BINV) In A Good Position To Invest In Growth?

Aug 16

We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully

Apr 09

Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth

Sep 01

We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely

Sep 28

Recent updates

Is BioInvent International (STO:BINV) In A Good Position To Invest In Growth?

Aug 16

We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully

Apr 09

Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth

Sep 01

Earnings Working Against BioInvent International AB (publ)'s (STO:BINV) Share Price Following 29% Dive

Jun 02

Analysts Are Betting On BioInvent International AB (publ) (STO:BINV) With A Big Upgrade This Week

Feb 25

We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely

Sep 28

Time To Worry? Analysts Just Downgraded Their BioInvent International AB (publ) (STO:BINV) Outlook

Aug 31

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BINV 'nin kısa vadeli varlıkları ( SEK1.0B ) kısa vadeli yükümlülüklerini ( SEK76.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: BINV şirketinin kısa vadeli varlıkları ( SEK1.0B ) uzun vadeli yükümlülüklerini ( SEK8.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BINV borçsuzdur.

Borcun Azaltılması: BINV son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BINV şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: BINV serbest nakit akışı her yıl % 17.9 2.6 yıl yetecek nakit akışına sahip olacaktır.

BioInvent International Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is BioInvent International (STO:BINV) In A Good Position To Invest In Growth?

We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully

Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth

We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely

Recent updates

BioInvent International AB (publ) to Report Q3, 2025 Results on Oct 29, 2025

Third quarter 2024 earnings released: kr1.48 loss per share (vs kr1.08 loss in 3Q 2023)

Insufficient new directors

New minor risk - Revenue size

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

Bioinvent International AB Announces the Enrollment of the First Patient in Triple Combination Arm of Phase 1/2A Study, Bi-1206, Rituximab and Calquence(R) for the Treatment of Non-Hodgkin's Lymphoma

Bioinvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program

Second quarter 2024 earnings released: kr2.09 loss per share (vs kr1.34 loss in 2Q 2023)

Is BioInvent International (STO:BINV) In A Good Position To Invest In Growth?

BioInvent Receives Notice of Allowance from USPTO for BI-1910 Patent Application

Bioinvent International AB Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 At PAGE 2024

BioInvent International Gains Patent for BI-1808 in China

BioInvent International AB Presents Promising Clinical Efficacy and Safety for Anti-Tnfr2 Agent BI-1808 At Asco 2024

Bioinvent to Present Additional Promising Phase 1/2A Data At EHA 2024 for BI-1206 with rituximab in NHL

First quarter 2024 earnings released: kr1.18 loss per share (vs kr1.12 loss in 1Q 2023)

Price target decreased by 23% to kr83.00

We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully

BioInvent International AB (publ) to Report Nine Months, 2024 Results on Oct 31, 2024

BioInvent International AB (publ), Annual General Meeting, May 03, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

BioInvent International AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024

New minor risk - Market cap size

BioInvent International AB (publ) Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607

Bioinvent Enrolls First Patient in Phase 1/2A Clinical Trial with TNFR2 Antibody BI-1910

BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial of BI-1808 as Single Agent

BioInvent Presents Preclinical Data at SITC Providing Clear Evidence of the Potential of Anti-TNFR2 Antibody BI-1910

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Bioinvent International AB Recruits First Patient in Single Agent Phase 2a Part of its Phase 1/2a Trial of its First-in-Class Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies

BioInvent International AB Initiates Subcutaneous Arm of Phase 1/2 Trial with BI-1206 in Solid Tumors

Independent Director recently bought kr603k worth of stock

Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Market cap size

Independent Director recently bought kr238k worth of stock

BioInvent International AB (publ) Reports Strong Interim Safety Data and Early Signs of Efficacy in Phase 1/2a Trial with Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies

BioInvent International AB Announces Abstract Presentation of BI-1206 At the 17th International Conference of Malignant Lymphoma 2023

BioInvent International AB Announces Additional Efficacy Data from Intravenous Part of Phase 1/2 Trial with BI-1206 in Solid Tumors

BioInvent Ready for Combination Studies with BT-001

Independent Chairman of the Board recently bought kr127k worth of stock

Earnings Working Against BioInvent International AB (publ)'s (STO:BINV) Share Price Following 29% Dive

Independent Chairman of the Board recently bought kr127k worth of stock

BioInvent International AB (Publ) Appoints of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs

High number of new directors

Forecast to breakeven in 2025

Full year 2022 earnings: Revenues exceed analyst expectations

Forecast to breakeven in 2025

Full year 2022 earnings released: kr0.69 loss per share (vs kr5.14 loss in FY 2021)

Analysts Are Betting On BioInvent International AB (publ) (STO:BINV) With A Big Upgrade This Week

Forecast to breakeven in 2025

BioInvent International AB (publ), Annual General Meeting, Apr 27, 2023

Bioinvent International AB Provides Update on Its Clinical and Pre-Clinical Pipeline, Including an Update on Its Lead Drug Candidate, the Novel Anti-Fc?RIIB Antibody Bi-1206

BioInvent International AB (publ) Receives FDA IND Approval for Anti-FcyRIIB Antibody BI-1607

Price target increased to kr113

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2024

We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely

Consensus revenue estimates increase by 130%

Price target increased to kr112

BioInvent International AB (publ) Completes Dose Escalation Part of the Phase I/IIa Study with Anti-TNFR2 Drug Candidate BI-1808

CASI Pharmaceuticals and BioInvent Announces Dosing of First Patient in BI-1206 Phase 1 Clinical Trial for the Treatment of Relapsed/Refractory Non-Hodgkin's Lymphoma in China

BioInvent International AB (publ) to Report Q2, 2023 Results on Aug 30, 2023

BioInvent International AB (publ) to Report Q1, 2023 Results on Apr 26, 2023

Consensus forecasts updated

Time To Worry? Analysts Just Downgraded Their BioInvent International AB (publ) (STO:BINV) Outlook

Price target increased to kr115

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

BioInvent International AB (publ) Enrolls First Patient in Phase 1/2A Trial of Bi-1607 in HER2 Positive Solid Tumors

Bioinvent International Resolves to Elect Natalie Berner and Nanna Lüneborg as New Board Members

Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001

Bioinvent International AB (Publ) Appoints Sylvie Ryckebusch as Chief Business Officer

Forecast to breakeven in 2023